The therapeutic efficacy of hormonal therapies to target estrogen receptor (ER)-positive BrCa is limited by the acquisition of ESR1 mutations, which confer treatment resistance to aromatase inhibitors (AIs). The gene discussed is CYP19A1; the disease is invasive breast carcinoma.